Corporate candidates to announce accelerate share buybacks: Trivariate
Seeking Alpha News (Tue, 14-Jan 9:00 AM ET)
Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600
PRNewswire (Tue, 19-Nov 5:56 PM ET)
Azenta to Participate in Stephens Annual Investment Conference
PRNewswire (Thu, 14-Nov 8:00 AM ET)
PRNewswire (Tue, 12-Nov 4:05 PM ET)
Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast
PRNewswire (Mon, 4-Nov 4:05 PM ET)
PRNewswire (Mon, 4-Nov 8:00 AM ET)
Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test
PRNewswire (Wed, 30-Oct 4:05 PM ET)
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
Azenta trades on the NASDAQ stock market under the symbol AZTA.
As of January 14, 2025, AZTA stock price declined to $51.44 with 343,873 million shares trading.
AZTA has a beta of 0.68, meaning it tends to be less sensitive to market movements. AZTA has a correlation of 0.06 to the broad based SPY ETF.
AZTA has a market cap of $2.35 billion. This is considered a Mid Cap stock.
Last quarter Azenta reported $170 million in Revenue and $.18 earnings per share. This beat revenue expectation by $462,000 and exceeded earnings estimates by $.08.
In the last 3 years, AZTA traded as high as $93.39 and as low as $36.01.
The top ETF exchange traded funds that AZTA belongs to (by Net Assets): IJR, VTI, VB, VBR, VXF.
AZTA has underperformed the market in the last year with a return of -21.0%, while SPY returned +23.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AZTA shares. However, AZTA has outperformed the market in the last 3 month and 2 week periods, returning +13.6% and +3.0%, while SPY returned +0.8% and -1.0%, respectively. This indicates AZTA has been having a stronger performance recently.
AZTA support price is $50.95 and resistance is $53.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZTA shares will trade within this expected range on the day.